2-[(2-oxopropyl)thio] imidazolium derivates

1,3,4,5-Tetramethyl-2-[(2-oxopropyl)thio]imidazolium chloride

10 mg 500 € available

Art. No. T101
Synonym L-682.777, SU732
Molecular Formula C10H17N2OS+Cl-
Molecular Weight 248,77
Purity by HPLC > 95% (HPLC)
Appearance off white solid
Solubility 50 mM in aqueous buffers
Dissolve e.g. 5.0 mg in 402 μl PBS buffer to obtain a 50 mM solution
or: 50 μM in 0.1% (v/v) DMSO / aqueous buffers.
Pre-dissolve e.g. 10.0 mg in 804 μl DMSO (50 mM).
Take e.g. 10 μl of the 50 mM stock solution - dilute by adding 9990 μl buffer or assay components to obtain your final assay solution (50 μM).
DMSO stock solutions are sterile and can be stored at -20°C for at least 6 months. To avoid too many freeze-thaw cycles, we strongly recommend storage of aliquots.
Application Inhibitor for transglutaminase.
The molecule was developed to block coagulation factor XIIIa, however the compound inhibits tissue transglutaminase as well. Both enzymes are inhibited with an IC50 of about 0.25 μM.
Storage Store at -20°C
Reference(s) Freund, K.F. et al. Biochemistry 1994, 33, 10109.
Lorand, L. et al. Exp. Eye Res. 1998, 66, 531.
Dale, G.L. et al. Nature 2002, 415, 175.
Dodt, J. et al. Anal. Biochem. 2013, 439, 145.
v.d. Akker J. et al. PLoS One 2011, 6, e23067.
Matlung, H.L. et al. Atherosclerosis 2010, 213, 77.
Barsigan C. et al., J. Biol. Chem. 1991, 266, 22501.
Katt, P.W. et al. Mol. Pharmaceutics 2015, 12, 46-55.
Aleman, M.M. et al. J. Clin. Invest. 2014, 124, 3590.
Aleman, M.M. et al. PLoS ONE 2015, 10, e0124448.
Kattula, S. et al. Blood Adv. 2018, 2, 25-35.
Macrae, F.L. et al. Clin Invest. 2018, 128, 3356-3368.
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification


  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering


  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy